Design evaluation and optimisation in multiple response nonlinear mixed effect models: PFIM 3.0.
about
Understanding and applying pharmacometric modelling and simulation in clinical practice and researchIntegrating dynamic mixed-effect modelling and penalized regression to explore genetic association with pharmacokineticsCombined Analysis of Phase I and Phase II Data to Enhance the Power of Pharmacogenetic Tests.The present and future of withdrawal period calculations for milk in the European Union: focus on heterogeneous, nonmonotonic data.Effect of Kidney Function on Drug Kinetics and Dosing in Neonates, Infants, and ChildrenUse of Modeling and Simulation in the Design and Conduct of Pediatric Clinical Trials and the Optimization of Individualized Dosing Regimens.Designing More Efficient Preclinical Experiments: A Simulation Study in Chemotherapy-Induced Myelosupression.Joint Model of Iron and Hepcidin During the Menstrual Cycle in Healthy WomenInfluence of the Size of Cohorts in Adaptive Design for Nonlinear Mixed Effects Models: An Evaluation by Simulation for a Pharmacokinetic and Pharmacodynamic Model for a Biomarker in OncologyAdvances in paediatric pharmacokinetics.Pharmacokinetics and Model-Based Dosing to Optimize Fludarabine Therapy in Pediatric Hematopoietic Cell Transplant Recipients.Model-Based Approach to Predict Adherence to Protocol During Antiobesity Trials.Pharmacokinetic interactions and dosing rationale for antiepileptic drugs in adults and children.Individual Bayesian Information Matrix for Predicting Estimation Error and Shrinkage of Individual Parameters Accounting for Data Below the Limit of Quantification.Optimal Design for Informative Protocols in Xenograft Tumor Growth Inhibition Experiments in Mice.What about confidence intervals? A word of caution when interpreting PTA simulations.Powers of the likelihood ratio test and the correlation test using empirical bayes estimates for various shrinkages in population pharmacokinetics.Optimal sampling times for a drug and its metabolite using SIMCYP(®) simulations as prior information.An MCMC method for the evaluation of the Fisher information matrix for non-linear mixed effect models.Design optimisation for pharmacokinetic modeling of a cocktail of phenotyping drugs.A limited sampling strategy based on maximum a posteriori Bayesian estimation for a five-probe phenotyping cocktail.An approach for identifiability of population pharmacokinetic-pharmacodynamic models.Current Use and Developments Needed for Optimal Design in Pharmacometrics: A Study Performed Among DDMoRe's European Federation of Pharmaceutical Industries and Associations Members.Optimal study design for pioglitazone in septic pediatric patients.Pharmacokinetic similarity of biologics: analysis using nonlinear mixed-effects modeling.Optimal designs for composed models in pharmacokinetic-pharmacodynamic experimentsPerformance comparison of various maximum likelihood nonlinear mixed-effects estimation methods for dose-response modelsMethods and software tools for design evaluation in population pharmacokinetics-pharmacodynamics studies.The effect of Fisher information matrix approximation methods in population optimal design calculations.Reevaluation of moxifloxacin pharmacokinetics and their direct effect on the QT interval.Design evaluation and optimization for models of hepatitis C viral dynamics.Prediction of shrinkage of individual parameters using the bayesian information matrix in non-linear mixed effect models with evaluation in pharmacokinetics.Design evaluation and optimisation in crossover pharmacokinetic studies analysed by nonlinear mixed effects models.Comparison of Nonmem 7.2 estimation methods and parallel processing efficiency on a target-mediated drug disposition model.Influence of covariance between random effects in design for nonlinear mixed-effect models with an illustration in pediatric pharmacokinetics.Development of an optimal sampling schedule for children receiving ketamine for short-term procedural sedation and analgesia.An evaluation of the operational model when applied to quantify functional selectivity.Optimal design of clinical trials with biologics using dose-time-response models.A general method to determine sampling windows for nonlinear mixed effects models with an application to population pharmacokinetic studies.Moxifloxacin versus placebo modeling of the QT interval.
P2860
Q28468334-B62C5495-B6CF-4E9D-B472-7C0589233556Q28650281-F805897F-16A5-4E18-8ACE-324ED462022EQ31074808-D5920EC5-E114-44C6-8B68-059DBF3AF737Q31127244-463E59D2-3856-4A2E-A285-1BCEE4894234Q36322918-5D2B66F8-16DC-47EB-AB6F-D3AB375CDDCDQ36473125-E45BED48-4529-469D-9B14-964FAAE3C4A4Q36618085-99BA4DF4-AA43-473D-90D3-0D994F2C584DQ36653945-BC14CB99-37C9-4133-B0F3-B81D61525295Q37742653-51284692-A729-4917-814B-A4AB7EF678A1Q37813680-275792B6-3145-43D3-8FE3-4912BEFD0594Q38374457-23273835-3827-4E23-8CC4-C70F9FA85C0EQ38600084-0899D8B5-C91B-4CD5-90EF-9A7F2E972006Q38620876-1A18F594-BFF6-4518-BA20-B1A41A3E39C1Q38703261-F23B7F5A-BA32-4B0A-8E72-5AA427139D2BQ38764274-7C841C71-733E-4058-8EAA-33300AB937F5Q38871384-5F556A98-BC29-4159-B6D4-D667971A9522Q39267478-C3404BD3-E513-4849-8C6C-20DEBDA58C0CQ39508318-8B638193-0876-49B2-AE79-D0389FCA1DEFQ39776721-78905586-717B-4263-9D3A-A78945786402Q40186641-B9B6DDC7-75C2-46B6-ACE7-B22B26E827DDQ40405015-CFA1B929-37B2-4913-84DB-B444D7A81451Q41454640-070065F0-EEDF-4E3C-A806-DBD73E399048Q41454771-9A5A9A82-24ED-467F-816C-09B5B5A50270Q41585973-419C1156-8057-412F-A936-DD2FDDDB390FQ41998537-EE2B3E3E-8670-4073-A7C3-EE3260AFF767Q42013526-598E350F-DEF3-483B-8E36-EE307B424CF3Q42218978-13F3EA4D-7BE4-4D92-A8B8-ECD2217B44CCQ42236437-32FBA11F-649D-4218-B1D7-5BA77C7EA0AEQ42368317-447A7D57-C2D2-44D2-8218-417568B5A927Q42694744-0D036F7C-4F7C-42A5-9458-167086A8C7E2Q43034515-C1A4892B-8E5F-4BFC-BE51-76CFF6A41AA7Q43406214-8E21ADB0-257E-4BB9-BE0D-D517645F3C2BQ45241474-E238FFFA-F075-4946-BE19-8B3D8EE15C42Q45338670-87F53188-CB32-4CE9-BA20-1AD4A4B9CDF1Q46058619-4F3164B8-D983-4223-8733-5B7391966B27Q47815521-68A79B10-EF2D-44CD-AB05-1EF3BC4DA59EQ49849104-459E360B-4BD4-46BF-990A-89764CB27558Q51039918-2314ECA7-1667-4CF9-9F45-5D779D545230Q51404243-D7F775F9-26F5-42B1-AD78-DA0D0C178F99Q51419723-D96CEF7B-0FBC-46CA-99D6-8F2DF7F09D58
P2860
Design evaluation and optimisation in multiple response nonlinear mixed effect models: PFIM 3.0.
description
2009 nî lūn-bûn
@nan
2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Design evaluation and optimisa ...... mixed effect models: PFIM 3.0.
@ast
Design evaluation and optimisa ...... mixed effect models: PFIM 3.0.
@en
Design evaluation and optimisa ...... mixed effect models: PFIM 3.0.
@nl
type
label
Design evaluation and optimisa ...... mixed effect models: PFIM 3.0.
@ast
Design evaluation and optimisa ...... mixed effect models: PFIM 3.0.
@en
Design evaluation and optimisa ...... mixed effect models: PFIM 3.0.
@nl
prefLabel
Design evaluation and optimisa ...... mixed effect models: PFIM 3.0.
@ast
Design evaluation and optimisa ...... mixed effect models: PFIM 3.0.
@en
Design evaluation and optimisa ...... mixed effect models: PFIM 3.0.
@nl
P2093
P1476
Design evaluation and optimisa ...... mixed effect models: PFIM 3.0.
@en
P2093
Caroline Bazzoli
France Mentré
Sylvie Retout
P356
10.1016/J.CMPB.2009.09.012
P577
2009-11-04T00:00:00Z